Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

3946 - The Prognostic Role of Indicators of Systemic Inflammatory Response in Patients with Glioblastoma


10 Sep 2017


Poster display session


Central Nervous System Malignancies


Vildan Kaya


Annals of Oncology (2017) 28 (suppl_5): v109-v121. 10.1093/annonc/mdx366


V. Kaya1, M. Yildirim2, G. Yazıcı3, A.Y. Yalçın4, N. Orhan5, A. Güzel6

Author affiliations

  • 1 Department Of Radiation Oncology, Medstar Antalya Hospital, 07000 - Antalya/TR
  • 2 İnternal Medicine, Bahçeşehir Üniversitesi, 27090 - Gaziantep/TR
  • 3 Department Of Radiation Oncology, Hacettepe University, Ankrar/TR
  • 4 Department Of Radiation Oncology, Suleyman Demirel University, Isparta/TR
  • 5 Department Of Biochemistry, Medicalpark Gaziantep Hospital, Gaziantep/TR
  • 6 Department Of Neurosurgery, Bahçeşehir Üniversitesi, 27090 - Gaziantep/TR


Abstract 3946


High-grade gliomas, among which glioblastomas are the most frequently observed histologic subtype, are the most common primary brain tumors in adults. The standard treatment for glioblastoma consists of maximal safe resection, followed by concomitant chemoradiotherapy. It was reported that inflammatory response plays a major role in malignancy, including tumor progression. This study aimed to determine the prognostic role of the neutrophil to lymphocyte ratio (NLR) and the thrombocyte to lymphocyte ratio (PLR)—both indicators of systemic inflammatory response (SIR)—in patients with glioblastoma.


This study retrospectively evaluated 90 patients that were treated for glioblastoma.


Median follow-up time was 11.3 months (range: 1-70 months). The 1-year and 2-year overall survival rates were 55.2% and 19.5%, respectively. Univariate analysis showed that there wasn’t a correlation between overall survival and gender (p = 0.184), comorbid diseases (p = 0.30), clinical presentation (p = 0.884), or tumor lateralization (p = 0.159). The prognostic factors that affected survival—other than SIR—were Eastern Cooperative Oncology Group (ECOG) performance status (p = 0.003), and tumor localization (p = 0.006). Multivariate analysis showed that overall survival was significantly correlated with SIR based on NLR (HR: 2.41), and ECOG performance status (HR: 1.53).


These findings confirm that the NLR value obtained from peripheral blood prior to treatment can be used as a prognostic factor in patients with glioblastoma. It is known that a high NLR value (NLR ≥5) is indicative of aggressive disease with decreased survival; therefore, aggressive treatment modalities can be offered to this selected patient population.

Clinical trial identification

Legal entity responsible for the study

Mustafa Yıldırım




All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.